Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its price target reduced by JPMorgan Chase & Co. from $18.00 to $17.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a neutral rating on the stock.

Other equities analysts also recently issued reports about the stock. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target for the company. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $12.08 on Friday. The firm’s 50-day moving average is $13.60 and its two-hundred day moving average is $24.14. Dyne Therapeutics has a 12 month low of $11.18 and a 12 month high of $47.45. The company has a market capitalization of $1.37 billion, a PE ratio of -3.39 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the 3rd quarter worth approximately $36,000. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $50,000. KBC Group NV grew its holdings in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in Dyne Therapeutics by 898.3% during the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after acquiring an additional 3,090 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.